612511-81-6

Basic information

• Product Name: (1-Methyl-1H-pyrazol-3-yl)methylamine
• Synonyms: (1-Methyl-1H-pyrazol-3-yl)methylamine;3-(Aminomethyl)-1-methyl-1H-pyrazole;(1-methyl-1H-pyrazol-3-yl)methanamine;(1-methyl-3-pyrazolyl)methanamine;(1-methylpyrazol-3-yl)methanamine;(1-methylpyrazol-3-yl)methylamine
• CAS NO: 612511-81-6
• Molecular Formula: C₅H₉N₃
• Molecular Weight: 111.14506
• Mol File: 612511-81-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 219.8 °C at 760 mmHg
• Flash Point: 86.7 °C
• Appearance: /
• Density: 1.16 g/cm³
• Vapor Pressure: 0.117mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.23±0.29(Predicted)
• CAS DataBase Reference: (1-Methyl-1H-pyrazol-3-yl)methylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (1-Methyl-1H-pyrazol-3-yl)methylamine(612511-81-6)
• EPA Substance Registry System: (1-Methyl-1H-pyrazol-3-yl)methylamine(612511-81-6)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 23-26-36/37/39-45
• Hazardous Substances Data: 612511-81-6(Hazardous Substances Data)

Usage

General Description

(1-Methyl-1H-pyrazol-3-yl)methylamine is a chemical compound with the molecular formula C6H9N3. It is a derivative of pyrazole with a methylamine group attached to the pyrazole ring. (1-Methyl-1H-pyrazol-3-yl)methylamine is commonly used as a reagent in organic synthesis, particularly in the formation of heterocyclic compounds. It has also been studied for its potential pharmacological properties, such as its activity as a ligand for metal complexes and its potential as a drug candidate. Additionally, it is considered to be a versatile building block in the development of various bioactive compounds.

InChI:InChI=1/C5H9N3/c1-8-3-2-5(4-6)7-8/h2-3H,4,6H2,1H3

Upstream product

• 79080-39-0 1-Methylpyrazole-3-carboxylic acid nitrile 
• 89179-62-4 1-methyl-1H-pyrazole-3-carboxamide 
• 17827-61-1 methyl ester of 1-methylpyrazole-3-carboxylic acid 
• 25016-20-0 1-methylpyrazole-3-carboxylic acid 

Downstream Products

• 1196886-83-5 2-amino-4-chloro-7-((1-methyl-1H-pyrazol-3-yl)methyl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one 
• 1400872-78-7 trans-N-[3-(2-{[(1-methyl-1H-pyrazol-3-yl)methyl]amino}pyrimidin-5-yl)imidazo[1,2-b]pyridazin-6-yl]cyclohexane-1,4-diamine 

Relevant articles and documents

5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER

The invention is directed to substituted 5-(1H-benzo[d]imidazo-2-yl)- pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives. Specifically, the invention is directed to compounds according to Formula (lb) wherein R', R2', R3', R4', Rs', R6', R7', and X1' are as defined herein; or a salt thereof including a pharmaceutically acceptable salt thereof. The compounds of the invention decrease MYC protein (c-MYC) in cells and/or inhibit p300/CBP histone acetyltransferase and can be useful in the treatment of cardiac hypertrophy, diabetes, obesity and nonalcoholic fatty liver disease, HIV, polycystic kidney disease, inflammatory diseases, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, cancer and pre-cancerous syndromes, and diseases associated with dysregulation of Myc or inhibition of p300/CBP histone acetyltransferase. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention still further discloses methods of reducing MYC protein (c-MYC) in cells and inhibiting p300/CBP histone acetyltransferase activity, and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.